Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTCH1 | P46531 | 7/20 | 0.38 |
| ▸ | RBPJ | Q06330 | 3/20 | 0.38 |
| ▸ | BDKRB1 | P46663 | 4/20 | 0.37 |
| ▸ | OXTR | P30559 | 2/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
| ▸ | NOTCH3 | Q9UM47 | 4/20 | 0.35 |
| ▸ | CCKBR | P32239 | 5/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4182589 | 1.00 | NOTCH1 (0.38) | NOTCH1RBPJBDKRB1OXTRPSEN1 | |
| SCHEMBL7593777 | 1.00 | NOTCH1 (0.38) | NOTCH1RBPJBDKRB1OXTRPSEN1 | |
| SCHEMBL4980551 | 1.00 | NOTCH1 (0.38) | NOTCH1RBPJBDKRB1OXTRPSEN1 | |
| SCHEMBL4175024 | 0.91 | BDKRB1 (0.42) | NOTCH1RBPJBDKRB1OXTRPSEN1 | |
| SCHEMBL4175020 | 0.91 | BDKRB1 (0.42) | NOTCH1RBPJBDKRB1OXTRPSEN1 | |
| SCHEMBL5515205 | 0.91 | BDKRB1 (0.42) | NOTCH1RBPJBDKRB1OXTRPSEN1 | |
| SCHEMBL4179536 | 0.89 | BDKRB1 (0.42) | NOTCH1RBPJBDKRB1OXTRPSEN1 | |
| SCHEMBL4179537 | 0.89 | BDKRB1 (0.42) | NOTCH1RBPJBDKRB1OXTRPSEN1 | |
| SCHEMBL4180350 | 0.88 | CCKAR (0.41) | OXTRCCKBR | |
| SCHEMBL4180352 | 0.88 | CCKAR (0.41) | OXTRCCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423033-B2 | Hydroxyalkanoylaminolactams and related structures as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-09-09 | — | — | US | claimed |
| US-20080132482-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-06-05 | — | — | US | claimed |
| US-20070027132-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Alphabeta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2007-02-01 | — | — | US | claimed |
| US-20050113363-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A beta protein production | OLSON RICHARD E (US) | 2005-05-26 | — | — | US | claimed |
| US-20030166636-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-09-04 | — | — | US | claimed |
| US-6503902-B2 | Treatment of neurological disorders related to beta -amyloid production such as Alzheimer's disease and Down's Syndrome. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | claimed |
| US-20090111793-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2009-04-30 | — | — | US | disclosed |
| US-7423033-B2 | Hydroxyalkanoylaminolactams and related structures as inhibitors of aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-09-09 | — | — | US | disclosed |
| US-20080132482-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2008-06-05 | — | — | US | disclosed |
| US-7112583-B2 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-09-26 | — | — | US | disclosed |
| US-6960576-B2 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-20050113363-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A beta protein production | OLSON RICHARD E (US) | 2005-05-26 | — | — | US | disclosed |
| US-20030166636-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A-beta protein production | OLSON RICHARD E (US) | 2003-09-04 | — | — | US | disclosed |
| US-6503902-B2 | Treatment of neurological disorders related to beta -amyloid production such as Alzheimer's disease and Down's Syndrome. | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-07 | — | — | US | disclosed |
| US-20020052360-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027132-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of Alphabeta protein production | APP, BACE1, APH1A | NOTCH1 625/4885RBPJ 2984/4885BDKRB1 3171/4885 |
| US-20080132482-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | APP, BACE1, APH1A | NOTCH1 575/4885RBPJ 2821/4885BDKRB1 3755/4885 |
| US-20030166636-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A-beta protein production | APP, APH1A, APH1B | NOTCH1 622/4885RBPJ 2748/4885BDKRB1 3539/4885 |
| US-20020052360-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of a beta protein production | APP, APH1A, BACE1 | NOTCH1 673/4885RBPJ 2934/4885BDKRB1 3670/4885 |
| US-20050113363-A1 | Hydroxyalkanoylaminolactams and related structures as inhibitors of A beta protein production | APP, BACE1, APH1A | NOTCH1 575/4885RBPJ 2821/4885BDKRB1 3755/4885 |
| US-20090111793-A1 | HYDROXYALKANOYLAMINOLACTAMS AND RELATED STRUCTURES AS INHIBITORS OF A BETA PROTEIN PRODUCTION | APP, BACE1, APH1A | NOTCH1 575/4885RBPJ 2821/4885BDKRB1 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.